"Bilirubin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A bile pigment that is a degradation product of HEME.
| Descriptor ID |
D001663
|
| MeSH Number(s) |
D03.383.129.578.840.249.184 D03.633.400.909.249.184 D04.345.783.249.184 D23.767.193.184
|
| Concept/Terms |
Bilirubin, Calcium Salt- Bilirubin, Calcium Salt
- Calcium Salt Bilirubin
- Salt Bilirubin, Calcium
- Calcium Bilirubinate
- Bilirubinate, Calcium
|
Below are MeSH descriptors whose meaning is more general than "Bilirubin".
Below are MeSH descriptors whose meaning is more specific than "Bilirubin".
This graph shows the total number of publications written about "Bilirubin" by people in this website by year, and whether "Bilirubin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 0 | 1 | 1 |
| 1997 | 2 | 1 | 3 |
| 1998 | 0 | 2 | 2 |
| 1999 | 0 | 1 | 1 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 4 | 4 |
| 2006 | 1 | 4 | 5 |
| 2007 | 0 | 6 | 6 |
| 2008 | 1 | 3 | 4 |
| 2009 | 0 | 2 | 2 |
| 2010 | 1 | 0 | 1 |
| 2011 | 2 | 4 | 6 |
| 2012 | 0 | 5 | 5 |
| 2013 | 2 | 5 | 7 |
| 2014 | 5 | 4 | 9 |
| 2015 | 5 | 0 | 5 |
| 2016 | 2 | 6 | 8 |
| 2017 | 1 | 3 | 4 |
| 2018 | 1 | 4 | 5 |
| 2019 | 0 | 4 | 4 |
| 2020 | 1 | 1 | 2 |
| 2021 | 1 | 4 | 5 |
| 2022 | 0 | 4 | 4 |
| 2023 | 1 | 6 | 7 |
| 2024 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Bilirubin" by people in Profiles.
-
Population-based screening strategies for biliary atresia in the newborn: A systematic review and meta-analysis. PLoS One. 2024; 19(8):e0307837.
-
A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis. N Engl J Med. 2024 Feb 29; 390(9):783-794.
-
Revisiting the Malignant Masquerade at the Liver Hilum: Have We Made Progress? Ann Surg Oncol. 2024 May; 31(5):3062-3068.
-
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis. N Engl J Med. 2024 Feb 29; 390(9):795-805.
-
Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis. Aliment Pharmacol Ther. 2024 01; 59(2):186-200.
-
Predicting hematoma expansion after intracerebral hemorrhage: The role of direct bilirubin. Am J Emerg Med. 2023 10; 72:193.
-
Unique Hemoglobinopathy Pattern Following Treatment with Voxelotor. Ann Clin Lab Sci. 2023 Jul; 53(4):647-652.
-
Autoimmune hepatitis presenting as acute liver failure: A 20-year retrospective review of North America. Liver Transpl. 2023 06 01; 29(6):570-580.
-
Serum bile acids as a prognostic biomarker in biliary atresia following Kasai portoenterostomy. Hepatology. 2023 03 01; 77(3):862-873.
-
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study. Liver Int. 2023 03; 43(3):695-707.